According to the official website of the Drug Evaluation Center of the National Medical Products Administration and public information, Shandong Xinbo Pharmaceutical Research Co., Ltd. (hereinafter referred to as "Shandong Xinbo") has assisted Jiuxu Pharmaceutical in obtaining implied permission for clinical trials of new drugs for "Nimodipine Fat Emulsion Injection" (acceptance number: CXHL2500665).

In the innovative research and development process of Nimodipine fat emulsion injection, Shandong Xinbo deeply participated with the professional positioning of research and development partners, relying on the core technology platform - clinical long-term intravenous infusion technology platform, to provide preclinical safety evaluation technical services covering the entire process for the drug. Shandong Xinbo, with its high standard technical solutions and rigorous service system, effectively promotes the project research and development process, ultimately helping cooperative enterprises successfully obtain clinical trial licenses.

Long term clinical intravenous drip platform
Long term intravenous administration technique in conscious rats and dogs, capable of continuous intravenous administration for 24 hours. Shandong Xinbo has established a continuous intravenous infusion technique for conscious rats and dogs for 3 months.

Jiuxu Pharmaceutical is a modern pharmaceutical enterprise that integrates planting, research and development, production, and sales. It is a national high-tech enterprise, a national postdoctoral research workstation, a Jiangsu province integrated enterprise, a Jiangsu province enterprise technology center, a Jiangsu province private technology enterprise, a Jiangsu province demonstration unit for intellectual property standardization, a Jiangsu province engineering technology research center for traditional Chinese medicine injection, a leading modern innovative traditional Chinese medicine enterprise in the 14th Five Year Plan of Xuzhou City, and a bank credit rating of AAA. It is a modern pharmaceutical enterprise mainly engaged in the research and development, production, and sales of cardiovascular and cerebrovascular, anti-tumor, anti infection, respiratory system, orthopedic, anesthetic and psychotropic drugs, hormones and other series of drugs.

Shandong Xinbo was established in April 2010, with Jinan Laboratory and Linyi Laboratory. It is a national high-tech enterprise, Shandong Enterprise Technology Center, Shandong Gazelle Enterprise, and a research service-oriented enterprise that integrates pharmacological research, toxicology research, drug analysis and testing services, animal pathology testing, and medical device evaluation services. We have completed preclinical safety evaluations for over 400 innovative drugs, including chemical drugs, traditional Chinese medicine and natural medicines, biological products, preventive and therapeutic vaccines, monoclonal antibodies, cell therapy products, medical devices, and other varieties.

Phone: 0531-68801033 0534-5056588
Website: www.xinbo.cn
Email: bd@xinbo.cn
Address: 5th Floor, Building A, Lishan International Cell Medicine Industrial Park, Jinan City, Shandong Province
No. 1308 Fumin Road, Linyi Economic Development Zone, Dezhou City, Shandong Province